Interventional Oncology Devices - Global Strategic Business Report

The global market for Interventional Oncology Devices was valued at US$2 Billion in 2025 and is projected to reach US$3 Billion by 2032, growing at a CAGR of 6.1% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Interventional Oncology Devices Market - Key Trends and Drivers Summarized

How Are Interventional Oncology Devices Advancing Cancer Treatment?

Interventional oncology devices are revolutionizing cancer treatment by offering minimally invasive procedures that target tumors with precision, reducing the need for traditional surgery and minimizing damage to surrounding tissues. These devices are used in image-guided procedures such as radiofrequency ablation (RFA), microwave ablation (MWA), and transarterial chemoembolization (TACE), which deliver targeted therapies directly to tumors. Interventional oncology treatments are increasingly being adopted for liver, lung, kidney, and bone cancers, providing patients with safer, less invasive alternatives to open surgery. These technologies are improving survival rates, reducing recovery times, and offering new hope to patients who may not be candidates for traditional surgery.

What Technological Innovations Are Driving Interventional Oncology?

Technological advancements in imaging modalities, robotics, and ablation techniques are driving the growth of interventional oncology. Innovations in imaging technologies, such as MRI, CT, and ultrasound, are enabling real-time, high-resolution visualization of tumors during procedures, improving the accuracy and safety of treatments. Robotic systems are enhancing the precision of interventions, allowing for better targeting of tumors in hard-to-reach areas. New ablation techniques, including microwave ablation and cryoablation, are providing more effective options for tumor destruction while minimizing damage to healthy tissues. These advancements are expanding the capabilities of interventional oncology and allowing for the treatment of a broader range of cancers.

How Do Market Segments Define the Growth of Interventional Oncology Devices?

Device types include ablation devices, embolization devices, and support devices, with ablation devices leading the market due to their widespread use in minimally invasive tumor destruction. Procedures include radiofrequency ablation, microwave ablation, and transarterial chemoembolization, with microwave ablation gaining popularity due to its higher efficacy in treating larger tumors. Cancer types treated with interventional oncology devices include liver, lung, kidney, and bone cancers, with liver cancer being the largest segment due to the high prevalence of hepatocellular carcinoma. The market is growing significantly in regions such as North America and Europe, driven by the availability of advanced healthcare infrastructure and the increasing adoption of minimally invasive treatments.

What Factors Are Driving the Growth in the Interventional Oncology Devices Market?

The growth in the interventional oncology devices market is driven by several factors, including the increasing incidence of cancer, the growing preference for minimally invasive treatments, and advancements in imaging and ablation technologies. As cancer rates rise globally, demand for less invasive and more targeted treatment options is increasing. Interventional oncology offers a solution by providing procedures that are less traumatic for patients and offer faster recovery times. Technological innovations in real-time imaging and precision ablation are further driving market growth by improving the effectiveness and safety of these treatments. Additionally, the rising adoption of interventional oncology in emerging markets, driven by improving healthcare infrastructure and access to advanced medical technologies, is contributing to the expansion of the market.

Report Scope

The report analyzes the Interventional Oncology Devices market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Device (Embolization Devices, Ablation Devices, Support Devices); Cancer Type (Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer, Other Cancer Types).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Embolization Devices segment, which is expected to reach US$1.8 Billion by 2032 with a CAGR of a 7%. The Ablation Devices segment is also set to grow at 5.2% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $536.3 Million in 2025, and China, forecasted to grow at an impressive 9.5% CAGR to reach $625.1 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Interventional Oncology Devices Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Interventional Oncology Devices Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Interventional Oncology Devices Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AngioDynamics, Inc., Boston Scientific Corporation, BTG plc, C. R. Bard, Inc., Cook Medical LLC and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Interventional Oncology Devices market report include:

• AngioDynamics, Inc.
• Boston Scientific Corporation
• BTG plc
• C. R. Bard, Inc.
• Cook Medical LLC
• EDAP TMS S.A.
• Healthtronics, Inc.
• IMBiotechnologies Ltd.
• Medtronic plc
• Merit Medical Systems, Inc.
• Neuwave Medical, Inc.
• Profound Medical Corp.
• Sirtex Medical Limited
• Teleflex Incorporated
• Terumo Corporation
• Trod Medical

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.